8ª Edição

Initial results from the phase III CheckMate 9ER trial show good prospects for first-line treatment with the combination of nivolumab and cabozantinib

per: Grupo Oncoclínicas
Initial results from the phase III CheckMate 9ER trial show good prospects for first-line treatment with the combination of nivolumab and cabozantinib

Scientific commission

André Fay
André Fay
Carlos Augusto Vasconcelos
Carlos Augusto Vasconcelos
Diogo Rosa
Diogo Rosa
Luiz Flávio Coutinho
Luiz Flávio Coutinho

Contributors

Diogo Rosa
Diogo Rosa
Mariane Fontes
Mariane Fontes

The results of the CheckMate 9ER study, presented at the ESMO 2020 Congress, have caught the attention of the medical oncology community and suggest yet another effective option for patients with metastatic kidney cancer who are candidates for first-line treatment.

The study compared two therapies: checkpoint inhibitor nivolumab plus the multikinase inhibitor cabozantinib versus sunitinib, a tyrosine kinase inhibitor, for first-line treatment of advanced renal clear cell carcinoma. The response rate for the cabozantinib + nivolumab regimen was 55.7% versus 27.1% for sunitinib. “The results are very encouraging and come to corroborate the superiority of using combinations (immunotherapy + immunotherapy or immunotherapy + TKI) in first line for patients with metastatic clear cell type kidney cancer,” comments Mariane Fontes, coordinator and oncologist of the uro-oncology group at Oncoclínicas Group, Rio de Janeiro.

The study compared two therapies: checkpoint inhibitor nivolumab plus multikinase inhibitor cabozantinib versus sunitinib, a tyrosine kinase inhibitor, for first-line treatment of advanced renal clear cell carcinoma. The response rate for the cabozantinib + nivolumab regimen was 55.7% versus 27.1% for sunitinib. “The results are very encouraging and come to corroborate the superiority of using combinations (immunotherapy + immunotherapy or immunotherapy + TKI) in first line for patients with metastatic clear cell type kidney cancer,” comments Mariane Fontes, coordinator and oncologist of the uro-oncology group at Oncoclínicas Group, Rio de Janeiro.

Access our website and read the full report.

Access the full article of this study
Download
Share
Or share the link
Link copied to your desktop.L